I can't comment on the least mean squared numbers, but will say this. The releases I have read, have been straight forward, very easy to understand and never misleading.
If you don't understand the difference between a primary and a secondary end point, or a trial that has been stated by the company to most likely be 1 of 2 required.... Its got to be your interpretation of the results that is causing you grief, and I would be careful taking advise from people on this chat board to try and read between the lines.
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-139
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.013(1.23%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | $1.01 | $2.161M | 2.115M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 129224 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 24065 | 18 |
View Market Depth
| Last trade - 14.18pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |